Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
41.48
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jun 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
42
43
Next >
Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts
August 29, 2023
To gain an edge, this is what you need to know today.
Via
Benzinga
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
August 29, 2023
The Biden administration is planning to negotiate the prices of 10 drugs in 2026.
Via
Investor's Business Daily
Coinbase Global, Bristol-Myers Squibb And 2 Other Stocks Insiders Are Selling
August 29, 2023
The Nasdaq 100 closed higher by over 100 points on Monday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
August 28, 2023
Via
Benzinga
Bristol-Myers Squibb Unusual Options Activity For August 21
August 21, 2023
Via
Benzinga
Check Out What Whales Are Doing With BMY
August 17, 2023
Via
Benzinga
2 Dividend Stocks to Buy Hand Over Fist
August 16, 2023
Both of these companies offer more than consistent income.
Via
The Motley Fool
A Step Closer To Cheaper Drugs For Americans: Price Negotiation And Its Implications
August 28, 2023
Some of the most frequently prescribed medications in the U.S. might soon become more affordable.
Via
Benzinga
Is Alexandria Real Estate Equities a Buy?
August 26, 2023
Great company, attractive valuation, lousy sector.
Via
The Motley Fool
Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government
August 25, 2023
AstraZeneca Plc (NASDAQ: AZN) announced its legal challenge against the U.S.
Via
Benzinga
GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus
August 24, 2023
Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that...
Via
Benzinga
Biotech Breakthroughs: 3 Companies on the Cusp of Major Discoveries
August 23, 2023
Here are just a few top biotech stocks that may be on the cusp of major, game-changing discoveries, thanks to AI.
Via
InvestorPlace
(BMY) - Analyzing Bristol-Myers Squibb's Short Interest
August 15, 2023
Via
Benzinga
2 Blue Chip Dividend Stocks That Are Top Buys in August
August 14, 2023
These two dividend-paying healthcare stocks stand out as top buys right now.
Via
The Motley Fool
Bristol Myers Squibb (BMY) Q2 2023 Earnings Call Transcript
July 27, 2023
BMY earnings call for the period ending June 30, 2023.
Via
The Motley Fool
3 Sorry Pharma Stocks to Sell in August Before It’s Too Late
August 22, 2023
Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell.
Via
InvestorPlace
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
August 21, 2023
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years.
Via
Talk Markets
Bristol Myers' Investigational Lung Cancer Candidate Shows High Response Rates
August 16, 2023
Bristol Myers Squibb & Co (NYSE: BMY) announced updated results from a TRIDENT-1 study, demonstrating that repotrectinib — a next-generation ROS1/TRK tyrosine kinase inhibitor (TKI) — continued to show...
Via
Benzinga
UnitedHealth Group, Pioneer Natural Resources And A Credit Card Giant: CNBC's 'Final Trades'
August 14, 2023
On CNBC’s "Halftime Report Final Trades," Karen Firestone of Aureus Asset Management named American Express Company (NYSE: BMY) as her
Via
Benzinga
Topics
Credit Cards
Exposures
Interest Rates
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
August 12, 2023
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies...
Via
Talk Markets
Pharma ETFs in Focus Post Q2 Earnings
August 11, 2023
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth.
Via
Talk Markets
Topics
ETFs
Bristol-Myers Squibb, Toast And A Major REIT Stock: CNBC's 'Final Trades'
August 11, 2023
On CNBC’s "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Bristol-Myers Squibb Company (NYSE: BMY), which announced $4 billion aggregate accelerated
Via
Benzinga
Should Dividend Investors Buy Bristol Myers Stock?
August 06, 2023
The drugmaker's near future may be bumpy, but it has a brighter future on the horizon.
Via
The Motley Fool
Looking for a Bargain? 7 Blue-Chip Stocks to Buy That Are Down 5% in 2023
August 01, 2023
These discounted blue-chip stocks boast robust underlying businesses which present amazing long-term upside potential ahead
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
July 31, 2023
Via
Benzinga
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
July 30, 2023
Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits.
Via
InvestorPlace
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
July 28, 2023
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
July 28, 2023
Via
Benzinga
Roku To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Friday
July 28, 2023
JP Morgan boosted the price target for Intel Corporation (NASDAQ: INTC) from $30 to $35. JP Morgan analyst Harlan Sur maintained an Underweight rating. Intel shares rose 6.8% to $36.91 in pre-market...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
July 28, 2023
Friday's session saw 59 companies set new 52-week lows.
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.